Fennec Pharmaceuticals Inc.
FENC
$6.01
-$0.27-4.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.54M | 49.35M | 48.89M | 44.95M | 21.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.54M | 49.35M | 48.89M | 44.95M | 21.25M |
| Cost of Revenue | 3.18M | 3.20M | 2.17M | 1.71M | 1.26M |
| Gross Profit | 44.35M | 46.15M | 46.72M | 43.24M | 19.99M |
| SG&A Expenses | 41.48M | 44.18M | 40.64M | 36.94M | 32.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.97M | 47.66M | 43.02M | 38.71M | 34.02M |
| Operating Income | 2.57M | 1.68M | 5.87M | 6.24M | -12.77M |
| Income Before Tax | -71.00K | -1.13M | 2.74M | 2.84M | -16.05M |
| Income Tax Expenses | 365.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.44 | -1.13 | 2.74 | 2.84 | -16.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -436.00K | -1.13M | 2.74M | 2.84M | -16.05M |
| EBIT | 2.57M | 1.68M | 5.87M | 6.24M | -12.77M |
| EBITDA | 3.37M | 4.28M | 9.45M | 14.47M | -- |
| EPS Basic | -0.01 | -0.04 | 0.10 | 0.10 | -0.60 |
| Normalized Basic EPS | 0.00 | -0.02 | 0.06 | 0.06 | -0.38 |
| EPS Diluted | -0.08 | -0.10 | 0.04 | 0.03 | -0.61 |
| Normalized Diluted EPS | -0.04 | -0.06 | 0.03 | 0.02 | -0.38 |
| Average Basic Shares Outstanding | 109.17M | 108.55M | 107.77M | 106.93M | 106.45M |
| Average Diluted Shares Outstanding | 113.22M | 112.59M | 111.82M | 110.98M | 106.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |